36 results about "First trimester" patented technology

The present invention provides a novel approach for identification and characterization of differentially represented fetal or maternal genomic regions in maternal circulation. Identification of overrepresented fetal genomic regions in the maternal circulation according to the present invention permit accurate analysis of fetal DNA without the need for enrichment or purification, which provides a simpler, more accurate and efficient prenatal diagnosis in early pregnancy. The present invention is particularly useful for noninvasive prenatal diagnosis during early pregnancy (e.g., during the first trimester).

The invention provides improved assays for detection of pregnancy. In the assays, pregnancy associated glycoproteins are analyzed in conjunction with progesterone analysis. The techniques of the invention overcome limitations in the prior art by reducing the rate of false positive results. The assays provided by the invention can be implemented to increase the efficiency of commercial animal breeding programs.

Gene expression patterns contemporaneous with early placental development in the first trimester of preeclamptic versus unaffected pregnancies have been obtained. Observation of differences in these gene expression patterns has allowed the identification of biomarkers that are useful in predicting and monitoring preeclampsia. These biomarkers are also useful in screening potential therapeutics for efficacy in the prevention or treatment of preeclampsia.

The invention discloses application of a compound traditional Chinese medicine composition to preparation of an inducing solution for directionally differentiating first trimester-derived perivascular cells as egg-like cells. The compound traditional Chinese medicine composition comprises the following bulk drugs in parts by weight: 18 to 30 parts of prepared rehmannia rhizome, 9 to 12 parts of dogwood, 8 to 16 parts of Chinese yam, 9 to 12 parts of barbary wolfberry fruit, 8 to 16 parts of south dodder seed and 8 to 16 parts of deer-horn glue. The invention also discloses the inducing solution and an inducing method for directionally differentiating the first trimester-derived perivascular cells as the egg-like cells. By virtue of the inducing solution, the first trimester-derived perivascular cells can be induced to be directionally differentiated as the egg-like cells. The inducing solution has great clinical application prospect.

The subject invention pertains to biomarkers for identifying a subject as having high risk of the development PE. The biomarkers presented herein include miRNAs, post-translational modification of histone proteins, amount, expression and/or activity of histone or DNA modifying enzymes and methylation of sites in the genomic DNA. In certain embodiments, increased miR-17, increased acetylation of H4 histone protein, decreased amount, expression and/or activity of HDAC5 mRNA or protein or increased methylation of DNA at the genomic site CYP19A1 in the blood, serum or plasma of a subject compared to that of a control subject is used to predict the development of PE in the subject. The invention also provides kits and reagents to conduct assays to quantify biomarkers described herein. The invention further provides the methods of treating and/or managing PE in a subject identified as having a high risk of the development of PE.

The invention relates to a enzyme predicted to be a serine protease, which is specifically expressed in association with embryo implantation and placentation in pregnant uterus. The enzyme of the invention is useful in the evaluation of fertility and monitoring of early pregnancy, placental development and function, fetal development, parturition, and conditions such as pre-eclampsia, intrauterine growth restriction, early abortion, abnormal uterine bleeding, endometriosis, and cancers, and may provide a potential target for contraception. It may also be important in diseases of the heart, testis or ovary, and may play a role in muscle function, including cardiac muscle, skeletal muscle, lung and the diaphragm. In addition the enzyme of the invention is useful in the screening of candidate drugs for fertility control or for treatment of fertility-related disorders.

The invention provides serum-based, diagnostic, biological assays for predicting disorders of pregnancy resulting from poor trophoblast and/or placental ischemia, including preeclampsia. Serum samples from such subjects exhibit an ability to disrupt the architecture involving fetal trophoblasts and maternal endothelial cells in a three-dimensional, dual cell co-culture system provided herein, in contrast to normal pregnancy serum samples. Based on these distinctions, the assays are employed to predict pregnancy outcomes as early as first trimester.

The invention discloses an exosome miRNA marker for early pregnancy diagnosis of ewes and application of the exosome miRNA marker. The exosome miRNA molecular marker comprises oar-miR-22-3p and chi-miR-378-3p. The miRNA molecular marker shows high expression in serum exosomes of ewes in early pregnancy, and when the serum exosome miRNA is independently used for diagnosing and distinguishing the ewes in early pregnancy from the ewes in non-pregnancy, ROC area under the curve (AUC) is 0.891 (0.728, 1.000), 0.922 (0.791, 1.000), respectively; the AUC (95% CI) of the exosome miRNA molecular markeris 0.984 (0.936, 1.000) when early pregnant ewes and non-pregnant ewes are distinguished through combined diagnosis, it can be seen that the exosome miRNA molecular marker has high sensitivity and high specificity in early ewe pregnancy diagnosis, multiple miRNA markers are combined, and superior diagnosis performance is obtained.

Provided is a non-invasive prenatal testing method based on whole-genome tendency scoring and adapted to test whether a pregnant woman's fetus has autosomal aneuploidy. The method includes: creating a database of m_k values which equal the averages of length proportions of health persons' chromosome k; obtaining the pregnant woman's and her fetus' chromosomal data y_k from the pregnant woman's plasma; obtaining p values by the ratio of the y_k values to the m_k values; and analyzing p values to determine whether the target chromosome has chromosome aneuploidy. The comparable data is increased and thus test accuracy is enhanced by comparing the p values and the p values in a database. Due to an abundance of comparable data, the method of the present invention is accurate even when performed in the first trimester, such that pregnant women can know as soon as possible whether their fetuses' chromosomes are normal.

The present invention relates to a method for assessing the likelihood of the presence or formation of fetal heart disease (such as HLHS) in a fetus. In this methodology, the mother, either before or during pregnancy, is tested for the presence of anti-strep antibodies. If positive, the fetus is evaluated and monitored for the presence of fetal heart disease; the fetus can be treated, if appropriate. In addition, either prior to pregnancy or during the first trimester, the mother can be treated to prevent the formation of such antibodies or to neutralize their presence or effect fetal heart tissue.

A method of isolating a pluripotent cell from human umbilical cord is described herein. The method involves collecting a sample of umbilical cord from fetal tissue obtained at less than 13 weeks of gestation, for example a first trimester umbilical cord. The sample is treated to obtain isolated umbilical cord cells, after which the isolated umbilical cord cells are incubated. Cells obtained in this way can be differentiated for use in treating conditions of cell damage, by supplanting the function of a damaged cell in a condition such as spinal cord injury, cardiovascular injury or heart disease.

The invention provides a method for detecting early pregnancy of cows. The method comprises the following steps of: collecting morning urine of cows or urine urinated 1-2 hours after last urination onthe seventh day to the fourteenth day after cows are mated; inserting HCG detection test paper of the cows into urine for 5-10 seconds, and indicating that a detection result is invalid if a test paper quality control line C does not develop color and a detection line T develops color; indicating that the HCG level of cows is low if the quality control line C develops color and the detection lineT does not develop color; comparing developed colors with an HCG colorimetric card if the quality control line C and the detection line T both develop colors; indicating that the cows are not pregnant if the HCG is less than 10mIU/ml; indicating that the cows are possibly pregnant and need to be continuously tested twice if HCG is greater than or equal to 10 mIU/ml; indicating that the cows are pregnant and have living embryos if the HCG of twice detection rises and the HCG detected later is 1-2 times of the HCG detected last time; and indicating that cows are pregnant but encounter embryo damage if the HCG of twice detection is kept unchanged or decreased, and taking miscarriage prevention measures or stopping pregnancy in time.

The invention provides a method for establishing a horseshoe kidney animal model. The method comprises: injecting a certain amount of retinoic acid solution at one time in the early pregnancy of the pregnant animal, and routinely feeding and giving birth to obtain the horseshoe kidney animal model. The method for creating an animal model of horseshoe kidney of the present invention has good experimental repeatability, and provides an experimental tool and platform for mechanism research for abnormal kidney development such as horseshoe kidney. Surgical operation and drug evaluation provide an extremely close and convenient experimental tool platform and scientific basis.

The invention discloses a biomarker for predicting pregnancy outcome of an infertility patient and application of the biomarker, and belongs to the technical field of biology and reproductive medicine. The biomarker for predicting the pregnancy outcome of the infertility patient is a quantity ratio of T-bet molecules to GATA3 molecules. Experiments show that the quantity ratio of the T-bet molecules to the GATA3 molecules can be used as a biomarker for predicting pregnancy outcome of infertility patients, and the biomarker can be used as a prediction and prevention target for early pregnancy failure of the infertility patients, and has positive pharmaceutical value and wide social significance. In addition, the invention also discloses a kit of the biomarker for predicting the pregnancy outcome of the infertility patient.

A pregnancy monitoring device and method improve detection in the first trimester of the occurrence of ectopic pregnancy and the occurrence of multiple foetuses. The device includes a sample absorbing member and an analyser to analyse a plurality of sequential a biological liquid samples and computing means to determine an ovulation date and deviations in the measured quantity of hCG from predetermined values which are indicators of ectopic pregnancy or multiple pregnancy. The device and method enables early detection of ectopic pregnancy or multiple pregnancy.

The invention discloses a novel biomarker for early abortion diagnosis, and particularly relates to a method for diagnosing, predicting and/or monitoring early abortion by hsa-miR-29a-3p and application of hsa-miR-29a-3p. According to the invention, hsa-miR-29a-3p is proposed as a marker for early pregnancy embryo implantation and bad pregnancy outcome for the first time, and then the regulation effect of hsa-miR-29a-3p on decidualization is proved by using an in-vitro endometrial stromal cell decidualization model. The temporal-spatial expression specificity based on the marker has wide clinical diagnosis and prediction application prospects. According to the specific expression of the hsa-miR-29a-3p in different pregnancy periods and in decidua tissues of early abortion, the early abortion of pregnancy can be effectively predicted and diagnosed.

The invention discloses a research method for traditional Chinese medicine physique distribution characteristics of nausea and vomiting in a gestation period, and belongs to the technical field of medical research. The method comprises: selecting a certain number of pregnant women at an early pregnancy stage as research objects; carrying out physique analysis on the research objects to obtain thephysique data of the research objects, wherein the physique analysis content comprises gentle physique analysis, yang deficiency physique analysis, yin deficiency physique analysis, qi depression physique analysis, qi deficiency physique analysis, damp-heat physique analysis, phlegm-damp physique analysis, allergic physique analysis and blood stasis physique analysis; and correspondingly performing data analysis on the physique data and the nausea and vomiting conditions of the research objects in a gestation period to obtain the traditional Chinese medicine physique distribution characteristic rule of nausea and vomiting in the pregnancy period is obtained. With the method, through physique detection, before pregnancy, the possible nausea and vomiting possibly occurring in an early pregnancy stage of women at an early pregnancy stage can be predicted and judged, and the corresponding suggestions are provided, so that adverse effects caused by nausea and vomiting in early pregnancy stage are reduced.

The invention belongs to the field of traditional Chinese medicine, and relates to a pharmaceutical preparation for treating early threatened abortion with positive anticardiolipin antibody and a preparation method thereof. The medicinal preparation is prepared from psoralen, Acanthopanax senticosus, Fengwei Qi, Lycium barbarum, Geshanxiao, willow parasitic, sagebrush, salvia, hairy potato and madder as medicinal raw materials. The whole recipe has few medicinal flavors, but the compatibility is reasonable, it can nourish the kidney and spleen, nourish the congenital in the future, qi to carry the fetus, blood to nourish the fetus, and tonic in the same day and day, so there is no damage. , No obvious toxic and side effects were found for mothers and infants, showing the great advantages of traditional Chinese medicine in the treatment of early threatened abortion, and it is worthy of further research and application.

The invention relates to the technical field of biomolecular markers, in particular to application of a PSAP gene in preparation of a product for detecting embryo death in an early stage of pig pregnancy. By means of Illumina sequencing, differential gene screening, bioinformatics analysis, qRT-PCR and other methods, it is determined that spontaneous death of porcine embryogenesis in the early pregnancy process is related to immunoreaction activity weakening of a maternal-fetal interface, and it is further screened and determined that the PSAP gene can serve as the early pregnancy porcine embryo spontaneous death molecular marker. Compared with a traditional observation method, the PSAP gene can be used for more accurately measuring spontaneously dead embryos in the early pregnancy process, and a new means is provided for scientific researchers for researching regulation and control of the embryonic development process and molecular mechanisms such as regulation and control of embryonic spontaneously dead and endometrium regulation and control.